Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Marinus Pharmaceuticals, Inc. - Common Stock
(NQ:
MRNS
)
0.5500
UNCHANGED
Last Price
Updated: 4:00 PM EST, Feb 10, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Marinus Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Nervous Markets Rebound As Ukraine Tensions Fade
↗
February 23, 2022
U.S. President Joe Biden said Russia had started to invade Ukraine and announced steps targeting Russia’s sale of sovereign debt abroad, its elites and a pair of banks.
Via
Talk Markets
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
February 23, 2022
Gainers Revelation Biosciences (NASDAQ:REVB) stock increased by 29.9% to $2.0 during Wednesday's pre-market session. The market value of their outstanding shares is at...
Via
Benzinga
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
↗
February 23, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase...
Via
Benzinga
Marinus Pharma Delays Status Epilepticus, IV Ganaxolone Clinical Trials Into 2023
↗
February 23, 2022
Marinus Pharmaceuticals Inc (NASDAQ: MRNS) expects data from the RAISE Phase 3 trial of ganaxolone in refractory status epilepticus in 2H of 2023. Earlier data from the trial...
Via
Benzinga
23 Stocks Moving in Wednesday's Pre-Market Session
↗
February 23, 2022
Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) rose 64.9% to $2.54 in pre-market trading after gaining around 5% on Tuesday. Roth Capital recently initiated coverage on the...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
February 22, 2022
Gainers Revelation Biosciences (NASDAQ:REVB
Via
Benzinga
Marinus Pharmaceuticals Announces Delay to RAISE Phase 3 Clinical Trial in Status Epilepticus and Associated IV Ganaxolone Clinical Trials
February 22, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals to Provide Business Update and Announce Preliminary Fourth Quarter 2021 Financial Results on March 21, 2022
February 16, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
February 10, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Completes In Vivo M2 Metabolite Study and Provides European Regulatory Update
February 03, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Canadian Biotech Disruptor Lexston Life Sciences is unlocking the God Molecule (LEXTF, ICPT, AKBA, QURE, BNTX, SAVA)
January 19, 2022
Via
AB Newswire
Topics
Bonds
Stocks
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
January 14, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright Bioconnect Conference
January 05, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
December 27, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces New Clinical and Research Data to be Presented at American Epilepsy Society Meeting
December 03, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Nine Presentations and Virtual Investor Event at American Epilepsy Society 2021 Annual Meeting
November 22, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences
November 15, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Recap: Marinus Pharmaceuticals Q3 Earnings
↗
November 09, 2021
Marinus Pharmaceuticals (NASDAQ:MRNS) reported its Q3 earnings results on Tuesday, November 9, 2021 at 08:00 AM. Here's what investors need to know about the...
Via
Benzinga
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2021 Financial Results
November 09, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 08, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals to Provide Business Update and Announce Third Quarter 2021 Financial Results on November 9, 2021
October 26, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Joins the Loulou Foundation in Collaboration on CANDID, a Comprehensive Observational Study in CDKL5 Deficiency Disorder
October 25, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 08, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Provides Strategic Update at Virtual R&D Event
October 05, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Virtual R&D Event on October 5, 2021
September 28, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of New Drug Application for Ganaxolone in CDKL5 Deficiency Disorder
September 20, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 09, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
European Medicines Agency Grants Marinus Pharmaceuticals Accelerated Assessment of Ganaxolone for Treatment of CDKL5 Deficiency Disorder
August 26, 2021
From
Marinus Pharmaceuticals, Inc.
Via
Business Wire
Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences
August 25, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
August 18, 2021
Gainers PharmaCyte Biotech (NASDAQ:PMCB) shares rose 119.0% to $7.49 during Wednesday's regular session. Trading volume for PharmaCyte Biotech's stock is 144.3...
Via
Benzinga
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
